Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-08-14 4:06 pm Purchase | 2026-06-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | BIOTECHNOLOGY VALUE FUND L P | 6,491,123 9.990% | 329,654 (+5.35%) | Filing History |
| 2026-08-14 10:38 am Purchase | 2026-06-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | T. Rowe Price Associates, Inc. | 3,825,950 6.200% | 3,825,950 (New Position) | Filing History |
| 2026-08-07 09:19 am Purchase | 2026-06-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | STATE STREET CORP STT | 3,668,627 6.000% | 3,668,627 (New Position) | Filing History |
| 2026-05-15 4:05 pm Purchase | 2026-03-31 | 13G | CULLINAN THERAPEUTICS INC CGEM | BIOTECHNOLOGY VALUE FUND L P | 6,161,469 9.990% | 242,988 (+4.11%) | Filing History |
| 2026-03-26 5:39 pm Sale | 2026-03-13 | 13G | CULLINAN THERAPEUTICS INC CGEM | VANGUARD GROUP INC | 0 0.000% | -3,298,504 (Position Closed) | Filing History |
| 2026-03-04 3:16 pm Purchase | 2025-12-31 | 13G | CULLINAN THERAPEUTICS INC CGEM | Kynam Capital Management, LP | 3,114,132 5.270% | 3,114,132 (New Position) | Filing History |
| 2026-02-17 4:10 pm Purchase | 2025-12-31 | 13G | CULLINAN THERAPEUTICS INC CGEM | BIOTECHNOLOGY VALUE FUND L P | 5,918,481 9.990% | 122,048 (+2.11%) | Filing History |
| 2026-01-30 1:27 pm Purchase | 2025-12-31 | 13G | CULLINAN THERAPEUTICS INC CGEM | VANGUARD GROUP INC | 3,298,504 5.580% | 355,179 (+12.07%) | Filing History |
| 2025-11-14 4:03 pm Sale | 2025-09-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | Citadel Advisors LLC | 1,988,907 3.400% | -1,020,219 (-33.90%) | Filing History |
| 2025-11-14 2:00 pm Sale | 2025-09-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | Lynx1 Capital Management LP | 5,766,090 9.800% | -2,782,994 (-32.55%) | Filing History |
| 2025-11-13 4:28 pm Sale | 2025-09-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | Deerfield Mgmt, L.P. | 2,927,013 4.950% | -356,811 (-10.87%) | Filing History |
| 2025-10-30 2:57 pm Sale | 2025-09-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | VANGUARD GROUP INC | 2,943,325 4.980% | -55,389 (-1.85%) | Filing History |
| 2025-10-10 6:53 pm Purchase | 2025-10-08 | 13G | CULLINAN THERAPEUTICS INC CGEM | Lynx1 Capital Management LP | 8,549,084 14.500% | 4,148,242 (+94.26%) | Filing History |
| 2025-08-14 06:58 am Purchase | 2025-06-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | Lynx1 Capital Management LP | 4,400,842 7.500% | 4,400,842 (New Position) | Filing History |
| 2025-08-06 6:55 pm Purchase | 2025-07-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | Citadel Advisors LLC | 3,009,126 5.100% | 3,009,126 (New Position) | Filing History |
| 2024-11-14 5:05 pm Sale | 2024-09-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | Blue Owl Capital Holdings LP | 2,010,972 3.450% | -1,408,870 (-41.20%) | Filing History |
| 2024-11-14 4:24 pm Purchase | 2024-09-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | BIOTECHNOLOGY VALUE FUND L P | 5,796,433 9.990% | 1,403,112 (+31.94%) | Filing History |
| 2024-11-12 2:23 pm Unchanged | 2024-09-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | VANGUARD GROUP INC | 2,998,714 5.170% | 0 (Unchanged) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | BlackRock, Inc. BLK | 4,338,725 7.500% | 0 (Unchanged) | Filing History |
| 2024-11-04 11:18 am Purchase | 2024-09-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | VANGUARD GROUP INC | 2,998,714 5.170% | 1,227,271 (+69.28%) | Filing History |